Convey Holding Parent Inc

CNVY 4 | $10.51 0.0%

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-0.5% 3d) (0.0% 7d) (239.48% volume)
Earnings Calendar:
Market Cap: $ 769,270,737
https://www.conveyhealthsolutions.com
Sec Filling | Patents | 3000 employees

Convey is a specialized healthcare technology and services company that is committed to providing clients with healthcare-specific, compliant member support solutions utilizing technology, engagement, and analytics. Convey's administrative solutions for government-sponsored health plans help to optimize member interactions, ensure compliance, and support end-to-end Medicare processes. By combining its purpose-built technology platforms with dedicated and flexible business process solutions, Convey creates better business results and better healthcare consumer experiences on behalf of business customers and partners. Convey's clients include some of the nation's leading health insurance plans and pharmacy benefit management firms. Convey's healthcare-focused teams help millions of Americans navigate the complex Medicare Advantage and Part D landscape.

optical ycombinator

add to watch list Paper trade email alert is off

Momentive Global Inc

MNTV | $9.45 7.6M

Information

(0.0% 1d) (0.0% 1m) (1.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (497.43% volume)
Earnings Calendar: 2023-08-09
Market Cap: $ 1,424,019,999
https://www.momentive.ai
Sec Filling | Patents | 1367 employees

Momentive (formerly SurveyMonkey) is a leader in agile experience management, delivering powerful, purpose-built solutions that bring together the best parts of humanity and technology to redefine AI. Momentive’s products, including GetFeedback, SurveyMonkey, and its brand and market insights solutions, empower ?decision-makers at 345,000 organizations worldwide to shape exceptional experiences. More than 20 million active users rely on Momentive for market insights, brand insights, employee experience, customer experience, and product experience. Ultimately, the company’s vision is to raise the bar for human experiences by amplifying individual voices.

brands

add to watch list Paper trade email alert is off

Proterra Inc

PTRA | $0.067 -25.56% -34.33% 58M

Manufacturing

(0.0% 1d) (0.0% 1m) (-93.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (21.78% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 15,262,600
https://www.proterra.com/
Sec Filling | Patents | 709 employees

(US) Proterra, Inc. operates as an automotive and energy storage company. The Company designs and manufactures electric transit buses and electric charging systems. Proterra serves customers worldwide.

energy automotive eletrical

add to watch list Paper trade email alert is off

iSpecimen Inc

ISPC | $0.2772 -6.07% -6.46% 280K

Professional, Scientific, and T...

(0.0% 1d) (19.4% 1m) (-81.8% 1y) (0.0% 2d) (-11.8% 3d) (3.4% 7d) (-74.26% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 2,598,663

Sec Filling | Patents | 75 employees

headquartered in lexington, ma, ispecimen is the marketplace for human biospecimens, providing researchers with the specimens they need from the patients they want. the privately held company has developed the ispecimen marketplace, an online platform connecting healthcare organizations that have access to patients and specimens with the scientists who need them. proprietary, cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. researchers easily and compliantly gain access to specimens to drive scientific discovery. partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. and ultimately, healthcare advances for all.

add to watch list Paper trade email alert is off

Lyell Immunopharma Inc

LYEL | $2.31 -5.33% -5.63% 780K

Professional, Scientific, and T...

(0.0% 1d) (27.1% 1m) (26.4% 1y) (0.0% 2d) (1.2% 3d) (9.4% 7d) (-28.34% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 588,903,971
https://lyell.com
Sec Filling | Patents | 189 employees

Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, Seattle and Bothell, Washington.

genetic t-cell renewable

add to watch list Paper trade email alert is off

The Real Brokerage Inc.

REAX | $3.83 2.68% 2.61% 600K

(0.0% 1d) (26.0% 1m) (213.4% 1y) (0.0% 2d) (7.2% 3d) (9.7% 7d) (59.65% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 689,100,777
https://www.joinreal.com
Sec Filling | Patents | 758 employees

The Real Brokerage Inc. operates as a technology powered real estate brokerage firm. The Company finds ways to make agents' lives better by creating financial opportunitnies for agents through a better agent plan, best in-class technology, revenue sharing, and equity. Real Brokerage customers in North America.

msa

add to watch list Paper trade email alert is off

Unicycive Therapeutics Inc

UNCY | $1.07 0.0% 180K

Professional, Scientific, and T...

(0.0% 1d) (-29.6% 1m) (-27.7% 1y) (0.0% 2d) (-7.0% 3d) (-1.8% 7d) (-46.76% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 37,189,387
https://unicycive.com
Sec Filling | Patents | 2021 employees

Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

treatment kidney

add to watch list Paper trade email alert is off